Teva price target raised to $26 from $24 at UBS

UBS raised the firm’s price target on Teva to $26 from $24 and keeps a Buy rating on the shares. UBS views duvakitug Phase 2 data in Q4 as an attractive catalyst for Teva’s stock, with significant upside and limited downside potential, the analyst tells investors in a research note. Beyond duvakitug, the firm sees scope for stock upside from a FY24 beat and raise and potential API sale.